Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment
May 02, 2024 07:00 ET
|
Pluri Inc.
Placental Mucosal Associated Invariant T (MAIT) cells are unique unconventional immune T cells which are particularly suitable for the treatment of solid tumors, a significant unmet medical needMAIT...
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
April 08, 2024 07:00 ET
|
Pluri Inc.
Pluri’s patent enables mass-scale production of immune cell therapiesNew patented technology is applicable for the expansion of a variety of immune cellsTechnology sets stage for potential immune cell...
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
March 28, 2024 07:15 ET
|
Pluri Inc.
HAIFA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
Pluri Inc. Announces 1-for-8 Reverse Share Split
March 27, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the “Company"), a leading biotechnology company that transforms cells into solutions, today...
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
March 21, 2024 07:00 ET
|
Pluri Inc.
International Coffee Organization (ICO) Market Report published on March 7, 2024 highlights alarming price instability challenging the coffee industryAccording to the report, adverse weather...
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
March 19, 2024 04:00 ET
|
Pluri Inc.
HAIFA, Israel, March 19, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions that promote...
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
March 14, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 14, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company"), a leading biotechnology company that transforms cells into solutions, today...
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
March 11, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 11, 2024 (GLOBE NEWSWIRE) -- In a strategic move that underscores its innovative edge in the agtech sector, Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or "the Company") today...
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
March 06, 2024 07:00 ET
|
Pluri Inc.
HAIFA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) (“Pluri” or the “Company”), a leading biotech company that transforms cells into solutions that promote...
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
February 28, 2024 07:00 ET
|
Pluri Inc.
Growing pipeline of industry-specific new potential products, services, collaborations and partnerships through PluriAgtech, PluriCDMO, PluriHealth, and PluriFoodRecent achievements include: new...